How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Read More
Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components. Download the full article to learn:…
Read More
This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS),…
Read More
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as "Doggybones." These linear constructs, which exclude unnecessary bacterial elements, demonstrated…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated…
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets new industry standards for speed, purity, and scalability, overcoming the…
Read More
